Endocan, Novel Potential Biomarker for Systemic Sclerosis: Results of a Pilot Study

@article{Blnescu2016EndocanNP,
  title={Endocan, Novel Potential Biomarker for Systemic Sclerosis: Results of a Pilot Study},
  author={Paul Bălănescu and Anca Lădaru and Eugenia Bălănescu and Theodor Voiosu and Cristian Băicuș and Gheorghe Andrei Dan},
  journal={Journal of Clinical Laboratory Analysis},
  year={2016},
  volume={30}
}
Systemic sclerosis (Ssc) is an autoimmune disease characterized by vascular alterations of small arteries and microvessels with subsequent tissue fibrosis. Endocan is expressed by endothelial cells and associated with endothelial dysfunction; therefore it could be a potential biomarker for Ssc patients. 
Validity of endocan as a biomarker in systemic sclerosis: relation to pathogenesis and disease activity
TLDR
Measure of the endocan level in systemic sclerosis patients' sera to test its relation to disease activity and treatment responses and to evaluate its specificity by comparing these data with Behcet’s disease and rheumatoid arthritis patients’ data. Expand
Endocan: A novel inflammatory indicator in cardiovascular disease?
TLDR
Endocan levels are elevated in conditions such as chronic kidney disease, renal transplant rejection, tumor progression and hypertension, and further studies are needed to assess the relevance of endocan in clinical practice. Expand
Endocan and Circulating Progenitor Cells in Women with Systemic Sclerosis: Association with Inflammation and Pulmonary Hypertension
TLDR
CD34+ cell number was significantly correlated with endocan levels and with sPAP in SSc;endocan and CD34+ progenitor cells might be suggested as a potential marker of disease status. Expand
The role of endocan and selected pro-inflammatory cytokines in systemic lupus erythematosus
TLDR
A higher serum level of endocan in SLE patients indicates its possible role in the pathogenesis of the disease and reflects endothelial dysfunction. Expand
Novel Biomarkers for Evaluation of Endothelial Dysfunction
TLDR
Novel biomarkers of endothelial dysfunction, particularly endothelial microparticles, endocan, and endoglin are focused on, and whether they fulfill the criteria to be applied in clinical practice are discussed. Expand
Endothelium biomarkers endocan and thrombomodulin levels in isolated coronary artery ectasia.
TLDR
The results suggest that endocan and thrombomodulin play an important role in the development of isolated CAE, and these markers were not associated with CAE severity as assessed using the Markis classification. Expand
Serum Level of Endothelial Cell-Specific Molecule -1 (ESM -1) as a New Potential Biomarker for Rheumatoid Arthritis Disease Activity
TLDR
Serum Level of Endothelial Cell-Specific Molecule -1 (ESM -1) as a New Potential Biomarker for Rheumatoid Arthritis Disease Activity is presented. Expand
An evaluation of biomarkers indicating endothelial cell damage, inflammation and coagulation in children with Henoch-Schönlein purpura
TLDR
Serum levels of biomarkers indicating endothelial cell damage, inflammation and coagulation in children with HSP, characterized by generalized vasculitis, were investigated. Expand
The diagnostic and prognostic value of serum endocan in patients with cirrhotic cardiomyopathy
TLDR
Endocan is a promising biomarker of severity of cirrhosis and may help in the diagnosis of cardiac dysfunction in this population of patients with liver cirrhotic cardiomyopathy. Expand
Association of metabolites reflecting type III and VI collagen formation with modified Rodnan skin score in systemic sclerosis – a cross-sectional study
TLDR
Investigation of blood-based biomarkers of type I, III and VI collagen formation in systemic sclerosis patients and their correlation to modified Rodnan skin score found these biomarkers could be useful in monitoring the disease and efficacy of treatment. Expand
...
1
2
...

References

SHOWING 1-10 OF 33 REFERENCES
Elevated serum levels of endocan in patients with psoriasis vulgaris: correlations with cardiovascular risk and activity of disease
TLDR
It is shown that endocan is a novel human endothelial cell‐specific molecule‐1 (endocan) that may be a novel endothelial dysfunction marker and associated with an increased risk of cardiovascular disease. Expand
Endocan—A Novel Inflammatory Indicator in Newly Diagnosed Patients With Hypertension
TLDR
The findings suggest that circulating endocan levels represent a new marker in patients with essential HT and may have a functional role in endothelium-dependent pathological disorders. Expand
Systemic sclerosis: a critical digest of the recent literature.
TLDR
A critical analysis of the most relevant studies regarding the pathogenesis, classification and management of systemic sclerosis is provided. Expand
Endocan and Atherosclerosis
TLDR
It is thought that hsCRP is satisfactory as a marker of inflammation in a pilot study; it has been widely used in that role. Expand
The vasculopathy of Raynaud's phenomenon and scleroderma.
TLDR
The regulatory mechanisms that contribute to this dysfunction and the vascular changes in the context of the other aspects of the SSc disease process are discussed in a novel attempt to integrate the individual pathologies of the disease process. Expand
Systemic sclerosis: a critical digest of the recent literature.
TLDR
A critical digest of the recent literature on systemic sclerosis is provided, with particular focus on the diagnosis, pathogenesis and treatment of the disease. Expand
Angiogenic cytokines and growth factors in systemic sclerosis.
TLDR
The authors' knowledge concerning the dysregulation of angiogenic homeostasis is largely incomplete and needs further research, for the future. Expand
Serum endocan levels as a marker of disease activity in patients with Behçet disease.
TLDR
In patients with BD, serum endocan levels correlated moderately but significantly with C-reactive protein, erythrocyte sedimentation rate, and disease activity, suggesting Circulating endocans may be a marker of BD activity. Expand
Serum endocan levels are increased in patients with inflammatory bowel disease.
TLDR
There is a potential role for endocan in future biomarker studies in IBD patients, and levels were significantly higher in the IBD group as compared to both healthy controls and cancer patients. Expand
Endocan, a novel marker of endothelial dysfunction in patients with essential hypertension: Comparative effects of amlodipine and valsartan
TLDR
It is suggested that amlodipine and valsartan decrease endocan levels in newly diagnosed hypertensive patients, which may contribute to the anti-inflammatory effects exerted by the two drugs on the vascular target. Expand
...
1
2
3
4
...